Statistics

Total Visits

Views
AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER-2 negative recurrent or metastatic BC: PFS analysis35

Select a period of time:

Number of views in the range

Views
AVALUZ study: First line with bevacizumab in combination with paclitaxel (P) and gemcitabine (G) in patients with HER-2 negative recurrent or metastatic BC: PFS analysis22

Views

Views
January 20250
February 20251
March 202515
April 20252
May 20251
June 20253
July 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore15
United States2
Brazil1
Spain1
Mexico1
Portugal1
Turkey1
 

Top cities views

Views
Council Bluffs1
Istanbul1